Novozymes Faces Slower Growth, Higher Risk, BofA Says, Reiterating Underperform

(PLX AI) – Novozymes faces slower growth and higher execution risk than peers, analysts at Bank of America said, keeping an underperform rating on the stock.Price target DKK 380 implies 15% downsideNovozymes aims to accelerate growth with a sharper …